CASE REPORT

Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report

Laura M. Szczesniak¹, Vincent J. Calleo² and Ross W. Sullivan²*

Abstract

Background: Patients with opioid use disorder (OUD) frequently present to the emergency department for acute treatment of overdose and withdrawal.

Case presentation: A 29-year-old male presented to the emergency room after intravenous heroin use followed by accidental ingestion of naltrexone. He was treated with buprenorphine with significant improvement in his Clinical Opioid Withdrawal Score, from moderately severe to mild withdrawal symptoms within a few hours.

Conclusion: Buprenorphine and minimal supportive care can be used to treat acute withdrawal precipitated by oral naltrexone in patients with OUD.

Keywords: Buprenorphine, Opioid use disorder, Overdose, Substance use treatment, Precipitated withdrawal, Naltrexone

Background

Opioid use disorder (OUD) is a public health emergency, with two out of three overdose deaths in 2018 involving an opioid [1]. In most cases, the Emergency Department (ED) is the primary location for acute treatment of these patients. If proper care is not provided to patients with OUD, they remain at a high risk for morbidity and mortality related to drug abuse.

The increased usage of the opioid antagonist naloxone has played a vital role in treatment of opioid overdose, but its use can lead to precipitated withdrawal, which is a rapid and intense onset of withdrawal symptoms. Several case studies have recently addressed the issue of precipitated withdrawal by treatment with buprenorphine [2–4], a partial opioid agonist that is traditionally used to treat symptoms of long-term withdrawal [5]. Patients in these studies were given buprenorphine after naloxone administration in order to alleviate acute symptoms, which resulted in a reduction in their Clinical Opioid Withdrawal Scores (COWS) [6].

Naltrexone is another opioid antagonist commonly used as abstinence in patients with opioid or alcohol dependence. Ingestion of naltrexone with measurable levels of opioids in the body can precipitate acute withdrawal, but withdrawal symptoms often appear more severe than usual [7]. One recent study found that elective naltrexone-induced withdrawal could be treated with buprenorphine in order to avoid methadone tapering and hasten treatment [8]. To the best of the authors’ knowledge, this is the first case of an accidental oral naltrexone ingestion after intravenous (IV) heroin use that was successfully treated by oral buprenorphine.

Case presentation

A 29-year-old male with a history of IV drug use presented to the ED with severe abdominal pain and vomiting. He reported injecting heroin...
morning, and approximately 10 min later ingested 50 mg naltrexone after confusing it with another medication. The patient was driving when he had a sudden onset of severe abdominal pain, approximately 1 h after naltrexone ingestion. After continuous 10/10 abdominal pain along with several episodes of emesis and hallucinations, he pulled his car over to the side of the road and was eventually brought to the ED by ambulance, arriving approximately 2.5 h after the naltrexone ingestion. On physical exam, he appeared distressed, diaphoretic, and agitated, with pressured speech. The CBC and BMP were within normal limits, except for decreased potassium (3.1 mmol/L) and increased glucose (163 mg/dL). VBG was significant for alkalosis (pH 7.56), hypocapnia (30 mmHg), decreased vSO2 (55%) and lactic acidosis (4.8 mmol/L).

The patient’s COWS was 26 on initial presentation (Table 1), indicating moderately severe opioid withdrawal [6]. He received 4 mg of IV ondansetron for severe nausea and vomiting, and the decision was made to treat remaining symptoms with buprenorphine. COWS for this patient and the drug administration timeline is shown in Fig. 1. Briefly, 2 mg of oral buprenorphine was administered, followed by 8 mg approximately 1 h after the first dose after little change in COWS was observed. Over the next 90 min, there was significant improvement in the COWS from 26 to 15. At that time, the patient was also administered IV famotidine, clonidine and diazepam. The COWS continued to improve, and within 3 h of presentation, the patient demonstrated only mild withdrawal symptoms. The last two recorded COWS were 3 and 6, respectively. He was discharged with instructions to follow up with the addiction center at this institution.

Since presentation, patient has continued IV drug use, but is being followed by our hospital addiction services.

Discussion and conclusions
Due to its unique properties as a partial mu agonist, buprenorphine is widely used as a treatment in the setting of long-term opioid withdrawal and OUD in order to deter patients from illicit opioid use or opioid abuse. Buprenorphine induction therapy is also increasingly being considered in the ED rather than through drug rehabilitation clinics due to the current public health crisis surrounding OUD [5]. While buprenorphine activates the mu receptor, it produces significantly less euphoria compared to full mu receptor agonists, such as morphine. However, buprenorphine binds to opioid receptors with a relatively high affinity, often displacing other opioids present in the body. Additionally, buprenorphine alone does not normally cause significant hypoventilation or sedation in adults, making its use in OUD treatment relatively safe and reduces the risk of overdose related to buprenorphine administration.

This patient was initially treated with 2 mg buprenorphine and closely observed due to the severity of withdrawal symptoms. When a repeat COWS indicated that withdrawal symptoms remained moderately severe, we chose to treat with another 8 mg buprenorphine. Without adjunct medications, this patient’s COWS improved from 26 to 15 within 90 min, and improved further to a score of 3 over the next 45 min (Fig. 1). It is important to note that famotidine, clonidine and diazepam were administered during this time, but we do not believe that these medications solely contributed to a further decline to a COWS of 3. GI upset

| Table 1 Patient COWS by individual category [6] |
|-----------------------------------------------|
| Time  | 1000 | 1100 | 1230 | 1315 | 1445 |
|-------|------|------|------|------|------|
| Resting pulse rate | 0    | 0    | 0    | 0    | 1    |
| Sweating | 2    | 2    | 2    | 1    | 1    |
| Restlessness | 3    | 3    | 3    | 0    | 0    |
| Pupil size | 2    | 2    | 1    | 1    | 1    |
| Bone or joint aches | 2    | 2    | 1    | 1    | 1    |
| Runny nose or tearing | 2    | 2    | 0    | 0    | 0    |
| GI upset | 5    | 3    | 3    | 0    | 0    |
| Tremor | 2    | 1    | 0    | 0    | 0    |
| Yawning | 1    | 1    | 0    | 0    | 1    |
| Anxiety or irritability | 2    | 4    | 2    | 0    | 0    |
| Piloerection (“gooseflesh skin”) | 5    | 5    | 3    | 0    | 0    |
| Score | 26   | 26   | 15   | 3    | 6    |

Fig. 1 Patient COWS during ED admission, with all treatments shown at the indicated times. O = ondansetron; B = buprenorphine; F/C/D = famotidine/clonidine/diazepam
and piloerection (Table 1) completely resolved within the 45 min of receiving these adjuncts, which most likely better reflects buprenorphine action.

We show that buprenorphine along with as-needed supportive care can be used to successfully treat acute precipitated withdrawal after accidental administration of an opioid antagonist, such as naltrexone. The relatively rapid induction (~ 30 min) and long half-life of buprenorphine (~ 37 h) makes its use ideal because it will maintain therapeutic levels for prevention of withdrawal symptoms. Although buprenorphine may cause initial worsening of withdrawal symptoms or COWS score in certain settings due to increased affinity of mu receptors for buprenorphine over other opioids, it ultimately is able to rapidly improve withdrawal symptoms and can eliminate the need for long-term supportive care.

Several case reports have been published recently demonstrating the efficacy of buprenorphine in acute opioid withdrawal, but only in cases of mild or moderate withdrawal, with COWS scores at buprenorphine induction ranging from 4 to 17 [2–4, 8]. We have presented a unique case demonstrating that buprenorphine is efficacious for significant reduction of withdrawal symptoms in moderately severe acute precipitated opioid withdrawal.

Acknowledgements
Not applicable.

Authors’ contributions
LS, VC, and RS conceptualized the case report. LS conducted the literature review. All authors have read and approved the final manuscript.

Funding
Not applicable.

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
All authors of the present manuscript declare that they have no conflict of interest. The case report was generated from existing data; consent to participate is not applicable.

Consent for publication
Not applicable.

Competing interests
There are no competing interests to report for this manuscript.

Author details
1 Department of Pharmacology, Upstate Medical University, 750 E Adams St, Syracuse, NY 13210, USA. 2 Department of Emergency Medicine, Upstate Medical University, 750 E Adams St, Syracuse, NY 13210, USA.

Received: 8 September 2020 Accepted: 24 September 2020 Published online: 07 October 2020

References
1. Wilson N, Kariisa M, Seth P, Smith HT, Davis NL. Drug and opioid-involved overdose deaths—United States, 2017–2018. MMWR Morb Mortal Wkly Rep. 2020;69:290–7.
2. Chhabra N, Aks SE. Treatment of acute naloxone-precipitated opioid withdrawal with buprenorphine. Am J Emerg Med. 2019;38:691-e3.
3. Herring AA, Schultz CW, Yang E, Greenwald MK. Rapid induction onto sublingual buprenorphine after opioid overdose and successful linkage to treatment for opioid use disorder. Am J Emerg Med. 2019;37:2259–62.
4. Phillips RT, Salzman M, Haroz R, Rafeq R, Mazzarelli AJ, Pelletier-Bui A. Elective naloxone-induced opioid withdrawal for rapid initiation of medication-assisted treatment of opioid use disorder. Ann Emerg Med. 2019;74:430–2.
5. Herring AA, Perrone J, Nelson LS. Managing opioid withdrawal in the emergency department with buprenorphine. Ann Emerg Med. 2019;73:481–7.
6. Wesson DR, Ling W. The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs. 2003;35:253–9.
7. Boyce SH, Armstrong PA, Stevenson J. Effect of inappropriate naltrexone use in a heroin misuser. Emerg Med J. 2003;20:381–2.
8. Ward HB, Barnett BS, Suzuki J. Rapid transition from methadone to buprenorphine using naltrexone-induced withdrawal: a case report. Subst Abuse. 2019;40:140–5.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more: biomedcentral.com/submissions